[ad_1]
The arrival of Moderna
Of the almost 300 vaccines put into production in record time, based on different platforms, two have received authorization from the US agency Fda: they are registered Pfizer-Biontech me Modern. Next year, the quantities of doses established by the centralized agreements of the European Commission will reach Italy, for a total of more than 202 million, in proportion to the inhabitants. Pfizer-Biontech plans to ship twice a week for a total of 26 million doses. The vaccination plan is flexible and will be structured according to the availability of the vials actually delivered. In the first quarter, the prophylaxis campaign in health workers will be completed to reach Covid-free hospitals. Then, operators and guests of nursing homes that in the first and second waves were exposed to the risk of outbreaks. Between one and the other 1.9 million people.
11 million doses
On January 6, the EMA should give the green light, again according to the emergency procedure, to the American Moderna vaccine, based on the same technology as the competitor: it requires a temperature of minus 20 degrees instead of minus 70, and it could be easier manageable. Around 11 million doses are expected. Meanwhile, the immunization campaign will have continued including patients with chronic diseases (7.4 million) and the elderly over 80 years (4.4 million), followed by 60-79 years (13.4 million). This phase depends on availability from March to summer. There will be vaccination centers marked by the Primula (1,500) and mobile units to get home to those who cannot move.
The AstraZeneca Times
This phase is linked to the result of the long-awaited AstraZeneca vaccine, developed in part by the Pomezia IRBM, from which the largest quantity should arrive, more than 40 million doses. After very promising results (the first publication of data in July), the Anglo-Swedish company had a setback for the dose used in the trial. Yesterday in an interview with Times The CEO of the multinational announced that the British drug agency could give the authorization as early as this week. Then the EMA exam. The remaining doses for Italy are from Janssen (the evaluation of the first Ema data has just started), Sanofi-GSK (late, ready not before the end of 2021) and Curevac (the third and final phase has just started from the human experimentation).
December 27, 2020 (change December 27, 2020 | 23:55)
© REPRODUCTION RESERVED
[ad_2]
